comparemela.com

Gurugram (Haryana) [India], October 8 (ANI/PRNewswire): Premas Biotech, developer of technologies & bioprocesses for novel proteins, today announced that Oravax Medical Inc., a US-based company that Premas Biotech is a shareholder in, reported positive preliminary data from its Phase 1 trial in South Africa of an oral Covid-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: - Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in the majority of the patients dosed - was observed in 75 per cent of the patients dosed - No safety issues were observed, including mild symptoms Oravax Medical is a clinical-stage vaccine company developing oral vaccines that combine Premas Biotech's D-Crypt Platform with Oramed Pharmaceuticals' POD technology. Oravax's oral Covid-19 vaccine candidate is designed using D-Crypt technology as a triple antigen VLP vaccine that targets three major surface proteins of the SARS-CoV-2 virus - Spike, Membrane and Envelope. This should allow the oral vaccine candidate to trigger a protective response not only against the prevalent strains of the SARS-CoV-2 virus but also the emerging mutations. "We're very encouraged by this initial data, which indicates that our platform can be safely and successfully used to orally deliver protein-based vaccines," said Nadav Kidron, Chairman of Oravax and CEO of Oramed Pharmaceuticals. "These results, together with the recent evolution of the Covid strains, further raise our confidence in the success of an oral Covid-19 vaccine and the broad potential of our platform along with Oramed's POD platform to explore oral vaccines for other infectious diseases," said Dr Prabuddha Kundu, Co-founder and Managing Director, Premas Biotech. About the Study An open-label, Phase 1, first-in-human, proof-of-concept, dose escalation, dose-finding trial in up to 24 healthy volunteers. The trial will evaluate the safety, tolerability, and immunogenicity of two concentrations of the Anti-SARS-CoV-2 vaccine administered orally as a two-dose schedule administered 21 days apart. The first cohort of 12 eligible subjects received one capsule containing the low dose on day 1 and a second oral dose on day 21. The ongoing trial is to include an additional 12 subjects (subjects 13-24) who are to receive a high dose on day 1 and a second dose on day 21. Subjects will be monitored for safety, tolerability and antibody titers for a period of 24 weeks after the first dose administration. An end-of-trial visit will take place 24 weeks after the first dose. Premas Biotech develops novel technologies & bioprocesses and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates. Premas' key focus areas are infectious diseases, cancer, metabolic disorders and inflammation. Besides D-CryptTM the difficult-to-express proteins expression platform, Premas' leading technologies include Axtex-4D: an ex-vivo tissueoid generation platform and C-Qwence: a fully human naive India-based scFv antibody library. Further information is available on the Company's website: www.premasbiotech.com Oravax Medical Inc. was established in 2021 by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech, MyMD Pharmaceuticals, and certain other shareholders, with a mission to bring an oral Covid-19 vaccine to the market. Oravax combines cutting-edge vaccine technology acquired from Premas Biotech and the proprietary POD oral delivery technology of Oramed Pharmaceuticals. For more information, please visit www.ora-vax.com Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901). For more information, please visit www.oramed.com. Company Contact Ambar Mehrotra Cell: +91 8968482266, Ph: +91-124-454 6600 contact@premasbiotech.com This story has been provided by PRNewswire. ANI will not be responsible in any way for the content in this article. (ANI/PRNewswire)

Related Keywords

South Africa ,United States ,India ,Israel ,Ambar Mehrotra ,Nadav Kidron ,Prabuddha Kundu ,Gurugram Haryana ,Oramed Pharmaceuticals Inc ,Mymd Pharmaceuticals ,Company Contact ,Oramed Pharmaceuticals ,Oravax Medical Inc ,Oramed Pharmaceuticals Nasdaq ,Premas Biotech ,D Crypt Platform ,Oramed Pharmaceutical ,Managing Director ,Protein Oral Delivery ,Gurugram Haryana India ,Ctober 8 Ani Prnewswire Premas Biotech ,Eveloper Of Technologies Amp Bioprocesses For Novel Proteins ,Oday Announced That Oravax Medical Inc ,A Us Based Company That Premas Biotech Isa Shareholder In ,Eported Positive Preliminary Data From Its Phase 1 Trial In South Africa Of An Oral Covid 19 Vaccine Candidate Results The First Cohort Include Significant Antibody Response 2 6 Fold Over Baseline As Measured By Multiple Markers Immune To Vlp Antigens Observed Majority Patients Dosed Was 75 Per Cent No Safety Issues Were ,Ncluding Mild Symptoms Oravax Medical Isa Clinical Stage Vaccine Company Developing Oral Vaccines That Combine Premas Biotech 39 Sd Crypt Platform With Oramed Pharmaceuticals Pod Technology 39s Covid 19 Candidate Is Designed Usingd Asa Triple Antigen Vlp Targets Three Major Surface Proteins Of The Sars Cov 2 Virus Spike ,Embrane And Envelope This Should Allow The Oral Vaccine Candidate To Triggera Protective Response Not Only Against Prevalent Strains Of Sars Cov 2 Virus But Also Emerging Mutations Quot We 39 Re Very Encouraged By Initial Data ,Hich Indicates That Our Platform Can Be Safely And Successfully Used To Orally Deliver Protein Based Vaccines ,Uot Said Nadav Kidron ,Hairman Of Oravax And Ceo Oramed Pharmaceuticals Quot These Results ,Ogether With The Recent Evolution Of Covid Strains ,Urther Raise Our Confidence In The Success Of An Oral Covid 19 Vaccine And Broad Potential Platform Along With Oramed 39s Pod To Explore Vaccines For Other Infectious Diseases ,Uot Said Dr Prabuddha Kundu ,Co Founder And Managing Director ,Remas Biotech About The Study An Open Label ,Phase 1 ,First In Human ,Proof Of Concept ,Dose Escalation ,Ose Finding Trial In Up To 24 Healthy Volunteers The Will Evaluate Safety ,Tolerability ,Nd Immunogenicity Of Two Concentrations The Anti Sars Cov 2 Vaccine Administered Orally Asa Dose Schedule 21 Days Apart First Cohort 12 Eligible Subjects Received One Capsule Containing Low On Day 1 Anda Second Oral Ongoing Trial Is To Include An Additional 13 24 Who Are Receivea High Will Be Monitored For Safety ,Olerability And Antibody Titers Fora Period Of 24 Weeks After The First Dose Administration An End Trial Visit Will Take Place Premas Biotech Develops Novel Technologies Amp Bioprocesses Partners With Global Biopharmaceutical Companies To Build Develop Biotherapeutic Vaccine Candidates 39 Key Focus Areas Are Infectious Diseases ,Dancer ,Etabolic Disorders And Inflammation Besidesd Crypttm The Difficult To Express Proteins Expression Platform ,Remas 39 Leading Technologies Include Axtex 4d An Ex Vivo Tissueoid Generation Platform Andc Qwencea Fully Human Naive India Based Scfv Antibody Library Further Information Is Available On The Company 39s Website Www Premasbiotech Com Oravax Medical Inc Was Established In 2021 By Oramed Pharmaceuticals ,He Largest Shareholder In Oravax ,Long With Premas Biotech ,Nd Certain Other Shareholders ,Itha Mission To Bring An Oral Covid 19 Vaccine The Market Oravax Combines Cutting Edge Technology Acquired From Premas Biotech And Proprietary Pod Delivery Of Oramed Pharmaceuticals For More Information ,Lease Visit Www Ora Vax Com Oramed Pharmaceuticals Nasdaq Tase Ormp Isa Platform Technology Pioneer In The Field Of Oral Delivery Solutions For Drugs Currently Delivered Via Injection Established 2006 ,Ith Offices In The United States And Israel ,Ramed Has Developeda Novel Protein Oral Delivery Pod Technology Oramed Is Seeking To Transform The Treatment Of Diabetes Through Its Proprietary Lead Candidate ,Rmd 0801 ,Hich Is Being Evaluated In Two Pivotal Phase 3 Studies And Has The Potential To Be First Commercial Oral Insulin Capsule For Treatment Of Diabetes Addition ,Ramed Is Developing An Oral Glp 1 Glucagon Like Peptide Analog Capsule Ormd 0901 For More Information ,Lease Visit Www Oramed Com Company Contact Ambar Mehrotra Cell 91 8968482266 ,H 91 124 454 6600 Contact Premasbiotech Com This Story Has Been Provided By Prnewswire Ani Will Not Be Responsible In Any Way For The Content Article ,

© 2025 Vimarsana

comparemela.com © 2020. All Rights Reserved.